Castle Biosciences Income Statement (2018-2026) | CSTL

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	22.76M	23.48M	25.04M	26.85M	34.84M	37.01M	38.34M	42.04M	50.14M	61.49M	66.12M	72.97M	87.00M	85.78M	86.31M	87.99M	86.19M	83.04M	87.01M	83.68M
Cost of Revenue (Quarter)	3.70M	4.50M	4.60M	5.94M	7.69M	8.86M	9.52M	10.18M	11.06M	11.32M	12.42M	13.89M	14.52M	15.61M	16.18M	16.38M	17.63M	18.70M	18.32M	20.53M
Gross Profit (Quarter)	19.06M	18.98M	20.44M	20.91M	27.15M	28.15M	28.82M	31.86M	39.08M	50.17M	53.70M	59.08M	72.48M	70.17M	70.13M	71.61M	68.56M	64.34M	68.69M	63.15M
Operating items
Amortization - Intangibles (Quarter)	0.26M	0.69M	0.96M	1.65M	2.10M	2.30M	2.17M	2.20M	2.25M	2.27M	2.30M	2.20M	2.25M	2.27M	2.10M	28.32M	1.96M	2.28M	2.24M	2.20M
Research & Development (Quarter)	6.79M	7.50M	9.45M	10.76M	11.93M	10.91M	11.31M	14.39M	13.31M	12.92M	12.99M	13.81M	14.14M	12.32M	11.77M	12.59M	12.79M	12.96M	13.52M	14.43M
Selling, General & Administrative (Quarter)	20.82M	22.59M	25.16M	30.45M	37.50M	36.63M	38.43M	46.76M	44.68M	44.62M	44.09M	48.49M	51.09M	50.50M	49.97M	58.62M	58.06M	55.91M	56.73M	64.90M
Other Operating Expenses (Quarter)	3.95M	5.19M	5.61M	10.15M	-10.62M	11.01M	11.44M	12.40M	13.31M	13.59M	14.69M	16.14M	16.77M	17.88M	20.52M	44.71M	19.59M	20.98M	20.59M	22.76M
Operating Expenses (Quarter)	31.57M	35.29M	40.21M	51.37M	38.81M	58.55M	61.17M	73.56M	71.30M	71.13M	71.78M	78.44M	81.99M	80.70M	82.26M	115.92M	90.44M	89.85M	90.84M	102.09M
Operating Income (Quarter)	-8.81M	-11.81M	-15.17M	-24.52M	-3.97M	-21.54M	-22.83M	-31.52M	-21.16M	-9.64M	-5.66M	-5.47M	5.01M	5.08M	4.05M	-27.93M	-4.25M	-6.80M	-3.83M	-18.41M
EBIT (Quarter)	-8.81M	-11.81M	-15.17M	-24.52M	-3.97M	-21.54M	-22.83M	-31.52M	-21.16M	-9.64M	-5.66M	-5.47M	5.01M	5.08M	4.05M	-27.93M	-4.25M	-6.80M	-3.83M	-18.41M
Non-operating items
Interest & Investment Income (Quarter)	0.02M	0.02M	0.02M	0.03M	0.37M	1.29M	2.27M	2.34M	2.40M	2.77M	3.12M	3.00M	3.14M	3.40M	3.37M	3.10M	2.94M	2.83M	2.90M	2.54M
Other Non Operating Income (Quarter)																		0.05M	0.10M	-0.44M
Non Operating Income (Quarter)																		0.05M	0.10M	-0.44M
Net income details
EBT (Quarter)	-8.79M	-11.79M	-15.15M	-24.49M	-3.60M	-20.25M	-20.56M	-29.19M	-18.76M	-6.87M	-2.54M	-2.49M	7.89M	8.28M	7.88M	-26.27M	-0.14M	-0.39M	-2.71M	-14.41M
Tax Provisions (Quarter)	0.01M		-1.77M	0.13M	-1.96M		0.06M	0.01M	0.02M	0.03M	0.04M	0.04M	-1.03M	6.01M	-1.71M	-0.42M	-4.67M	0.12M	-0.38M	0.11M
Profit After Tax (Quarter)	-8.79M	-11.79M	-6.43M	-24.62M	-1.65M	-20.25M	-20.62M	-29.20M	-18.78M	-6.91M	-2.58M	-2.53M	8.92M	2.27M	9.59M	-25.85M	4.52M	-0.50M	-2.33M	-14.52M
Equity Income (Quarter)															0.56M	-1.43M	1.19M	3.60M	-1.85M	2.02M
Income from Continuing Operations (Quarter)	-8.79M	-11.79M	-13.38M	-24.62M	-1.65M	-20.25M	-20.62M	-29.20M	-18.78M	-6.91M	-2.58M	-2.53M	8.92M	2.27M	9.59M	-25.85M	4.52M	-0.50M	-2.33M	-14.52M
Consolidated Net Income (Quarter)	-8.79M	-11.79M	-13.38M	-24.62M	-1.65M	-20.25M	-20.62M	-29.20M	-18.78M	-6.91M	-2.58M	-2.53M	8.92M	2.27M	9.59M	-25.85M	4.52M	-0.50M	-2.33M	-14.52M
Income towards Parent Company (Quarter)	-8.79M	-11.79M	-13.38M	-24.62M	-1.65M	-20.25M	-20.62M	-29.20M	-18.78M	-6.91M	-2.58M	-2.53M	8.92M	2.27M	9.59M	-25.85M	4.52M	-0.50M	-2.33M	-14.52M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-8.79M	-11.79M	-13.38M	-24.62M	-1.65M	-20.25M	-20.62M	-29.20M	-18.78M	-6.91M	-2.58M	-2.53M	8.92M	2.27M	9.59M	-25.85M	4.52M	-0.50M	-2.33M	-14.52M
Additional items
EPS (Basic) (Quarter)	-0.35	-0.47	-0.25	-0.97	-0.06	-0.77	-0.79	-1.10	-0.70	-0.26	-0.09	-0.09	0.32	0.08	0.35	-0.90	0.16	-0.02	-0.07	-0.49
EPS (Weighted Average and Diluted) (Quarter)	-0.35	-0.47	-0.25	-0.97	-0.06	-0.77	-0.79	-1.10	-0.70	-0.26	-0.09	-0.09	0.31	0.08	0.32	-0.90	0.15	-0.02	-0.07	-0.49
Shares Outstanding (Weighted Average) (Quarter)	25.00M	25.29M	25.14M	25.42M	25.75M	26.32M	26.05M	26.61M	26.73M	26.83M	26.80M	27.48M	27.65M	27.66M	27.78M	28.61M	28.76M	29.07M	28.99M	29.89M
Shares Outstanding (Diluted Average) (Quarter)	25.00M	25.29M	25.14M	25.42M	25.75M	26.32M	26.05M	26.61M	26.67M	26.83M	26.80M	27.48M	28.54M	29.40M	29.25M	28.61M	29.55M	28.87M	28.99M	29.89M
EBITDA (Quarter)	-8.79M	-11.79M	-6.43M	-24.62M	-1.65M	-21.54M	-22.83M	-31.52M	-21.16M	-9.64M	-5.66M	-5.47M	5.01M	5.08M	4.05M	-27.93M	-4.25M	-6.80M	-3.83M	-18.41M
Interest Expenses (Quarter)			0.00M	0.00M	0.00M	0.01M	0.00M	0.00M	0.00M	0.00M	0.00M	0.01M	0.27M	0.20M	0.09M	0.02M	0.02M	0.02M	0.02M	0.13M
Tax Rate (Quarter)	-0.06%		11.71%	-0.55%	54.29%		-0.28%	-0.05%	-0.09%	-0.47%	-1.53%	-1.81%	-13.11%	72.60%	-21.62%	1.61%	3,262.94%	-29.79%	14.08%	-0.76%

Research Tools

Castle Biosciences Income Statement (2018-2026) | CSTL

Create an account

Sign In

Reset Password